Future microbiology, 2017-05, Vol.12 (6), p.473-480
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus
- Ist Teil von
- Future microbiology, 2017-05, Vol.12 (6), p.473-480
- Ort / Verlag
- England: Future Medicine Ltd
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1746-0913eISSN: 1746-0921DOI: 10.2217/fmb-2016-0234Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5618940
- Format
- –
- Schlagworte
- Antibiotics, Azabicyclo Compounds - pharmacology, beta-Lactamase Inhibitors - pharmacology, beta-Lactams - pharmacology, Carbapenems, Carbapenems - pharmacology, Chronic illnesses, Clinical isolates, Cystic fibrosis, Drug resistance, Drug Resistance, Multiple, Bacterial, Ertapenem, Infections, Laboratories, Microbial Sensitivity Tests, Minimum inhibitory concentration, Mycobacterium abscessus, Mycobacterium abscessus - drug effects, Mycobacterium Infections, Nontuberculous - microbiology, Panipenem, Patients, Short Communication, Thienamycins - pharmacology, β-Lactam antibiotics